Clinical trials: CtDNA
Aggressive B-cell Lymphomas
Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell Lymphomas
RT4 (REAL TIME TAILORED THERAPY) study was designed as a national, multicenter proof of concept aiming to demonstrate the technical and operational capacity of the French Connect network and the Positron Emission Tomography (PET)…
- Trial name
- RT4 (NCT07514715)
- Testing
- blood test
- Where
- 30 sites in France
- Volunteers
- 129 people
- Sponsor
- The Lymphoma Academic Research Organisation
Melanoma (Skin)
Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma
BRAF V600-mutant metastatic melanoma are commonly treated using a combination of anti-BRAF and anti-MEK tyrosine kinase inhibitors (TKIs).
- Trial name
- OPTIMEL (NCT03416933)
- Testing
- Blood sampling
- Where
- 4 sites in France
- Volunteers
- 35 people
- Sponsor
- Institut de Cancérologie de Lorraine
Gastric Cancer
Potential Clinical Utilities of Circulating Tumor DNA in Gastric Cancer
This study is designed to evaluate the potential clinical utility of ctDNA in the field of gastric cancer treatment,especially the usage of an indicator of MRD(minimal residual disease) in post radical gastrectomy patients.
- Trial name
- NCT04000425
- Testing
- AVENIO ctDNA surveillance kit
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Shanghai Zhongshan Hospital
Cancer, Breast Cancer
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the…
- Conditions
- Cancer, Breast Cancer, Lung Cancer, Colon Cancer
- Trial name
- LIBERATE (NCT03702309)
- Where
- Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer Resectable
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Short-term relapse and poor survival are prevalent in patients with pancreatic adenocarcinoma (PAAD) after surgeries. Despite the importance of adjuvant treatments for resected PAAD patients, there is currently no suitable…
- Trial name
- NCT05479708
- Testing
- ctDNA-based MRD detection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- BAIYONG SHEN
Metastatic Cancers
Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.
The goal of this observational study is to investigate the real-world treatment landscape of patients with metastatic cancer and determine the role of ctDNA in monitoring treatment response in patients with metastatic cancer who…
- Trial name
- GS_ZKM (NCT06929910)
- Where
- Vietnam
- Volunteers
- 200 people
- Sponsor
- Gene Solutions
Colorectal Neoplasms, Trifluridine and Tipiracil
Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
This trial is a randomized, double-blind, multinational Phase III study to evaluate the efficacy and safety of preemptive treatment with FTD/TPI compared with administration of placebo as follow-up, which is the standard of care…
- Conditions
- Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA
- Trial name
- ALTAIR (NCT04457297)
- Testing
- trifluridine and tipiracil
- Where
- 39 sites in Japan, Taiwan
- Volunteers
- 243 people
- Sponsor
- National Cancer Center Hospital East
Lung Cancer
To Establish a Molecular Typing System for Early Diagnosis of Lung Cancer
This topic to take large multicenter study real world, the advanced liquid biopsy will ctDNA methylation detection technique is applied to pulmonary nodules differential diagnosis and early lung cancer screening, validation of…
- Trial name
- NCT05432128
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Singlera Genomics Inc.
Non Small Cell Lung Cancer, Complete Surgical Resection
Using ctDNA to Determine Therapies for Lung Cancer
This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with…
- Conditions
- Non Small Cell Lung Cancer, Complete Surgical Resection, Circulating Tumor DNA
- Trial name
- ctDNA Lung RCT (NCT04966663)
- Testing
- Nivolumab, Pemetrexed, Gemcitabine
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- University Health Network, Toronto
Metastatic Breast Cancer
Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer
The purpose of this study is to evaluate whether increased mutant ESR1 allele fraction in plasma ctDNA 3-6 weeks after initiating salvage endocrine therapy is predictive of progression free survival in patients with ER+…
- Trial name
- NCT03161834
- Testing
- Observational
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lung Cancer, NSCLC
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy.
- Trial name
- NCT04367311
- Testing
- Atezolizumab, Docetaxel, Cisplatin
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nasser Hanna
Colorectal Cancer Metastatic
Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
In North America, colorectal cancer patients with resectable liver-restricted metastases (mCRC-LR) are treated with approximately 6 months of preoperative systemic multi-agent chemotherapy.
- Trial name
- eDetect-mCRC (NCT05068531)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Gastric Cancer
ctDNA-MRD Monitoring After Resection in Gastric Cancer
Numerous studies have demonstrated that circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has significant clinical value in postoperative recurrence monitoring, adjuvant treatment decision-making, and…
- Trial name
- MRD-GC (NCT06893133)
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Peking University
Pancreatic Ductal Adenocarcinoma (PDAC), NGS Monitor MRD
ctDNA Monitoring After Pancreatic Cancer Surgery (K-4CARE Lite Study)
Pancreatic ductal adenocarcinoma (PDAC) carries one of the worst prognoses among solid tumors. Even after curative-intent resection, 70-80% of patients recur within two years.
- Trial name
- K4CARE-PDAC (NCT07597252)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Chang Gung Memorial Hospital
Cancer, Head and Neck Squamous Cell Carcinoma
Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma
This research study will include patients with high risk locally advanced head and neck squamous cell carcinoma (LA-HNSCC) of the oral cavity, oropharynx, hypopharynx or larynx and patients that are starting on standard…
- Conditions
- Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT04599309
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University Health Network, Toronto
Liver Metastases, Colorectal Cancer
Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases
Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort underwent curative resection after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant…
- Conditions
- Liver Metastases, Colorectal Cancer, Surgery, Circulating Tumor DNA
- Trial name
- NCT06404593
- Testing
- Blood sampling
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Peking University Cancer Hospital & Institute
Nodule Solitary Pulmonary, Non-small Cell Lung Cancer
Biomarkers for Risk Stratification in Lung Cancer
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco…
- Trial name
- NCT03774758
- Testing
- Guardant Health ct-DNA LUNAR assay
- Where
- 3 sites in United States
- Volunteers
- 1,440 people
- Sponsor
- University of California, San Francisco
Rectal Cancer
Response Assessment by Circulating Tumor DNA in Patients With Locally Advanced Rectal Cancer
This is a single-arm observational study to determine the feasibility of assessing tumor response utilizing Circulating tumor DNA (ctDNA) in patients of with locally advanced rectal cancer (LARC) undergoing standard-of-care total…
- Trial name
- NCT04670588
- Testing
- Circulating tumor DNA(ctDNA) level measurement
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Prostate Cancer
Circulating Tumor DNA in High Risk Localized Prostate Cancer
This prospective, non-therapeutic translational biomarker study will collect blood in patients with high risk localized prostate cancer prior to prostatectomy.
- Trial name
- NCT07222436
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Pittsburgh
Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine…
- Trial name
- SIENNA (NCT06634199)
- Testing
- Durvalumab
- Where
- 22 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Fundación GECP